Based on R&D strategic reasons, our co-development Partner financing the study disengaged from the development of GNbAC1.

The humanised IgG4 monoclonal antibody GNbAC1 targets the envelope protein (Env) of the human endogenous multiple sclerosis-associated retrovirus (HERV-W MSRV), which may play a critical role in multiple sclerosis.

The study assesses the long-term safety of GNbAC1 in patients with RRMS and the long-term efficacy of GNbAC1 in terms of MRI outcomes, relapse rate, disability and disease progression.

Main Inclusion Criteria:

• Patients must have completed Period 2 of study GNC-003 and must meet all eligibility criteria for the GNC-004 study
• Patients (male or female with reproductive potential) must agree to use highly effective methods of birth control
• Provision of written informed consent to participate prior to any trial procedure as shown by signature on the subject consent form.

Main Exclusion Criteria:

• Patients not having completed the study GNC-003
• Pregnancy
• The emergence of any disease diagnosis during the course of study GNC-003 that is not MS and could better explain the patient's neurological signs and symptoms